PATENT CLAIM ANALYSIS

Application Number: 16467866
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-10
Patent Classification: ["514", "220000"]

Abstract:
The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.

Claim (Index 11):
Use of the hydrobromide as claimed in  claim 3  in the manufacture of an injection having the effect of sedation, hypnosis, anti-anxiety, inducing muscle relaxation, anticonvulsant or anesthesia.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 100.0
- Lexical Diversity: 1.41538
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15539147', '11963192', '14429388', '15703945', '16096136']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7920626443480011
- 35 USC 102 Novelty (BERT): 0.525313607723374
- Combined Prediction Score: 0.7653877406855385
- Mean Citation Score: 252.082194
- Max Citation Score: 267.071
- Similarity Product: 133.30133633363252

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test